Advanced Malignancies Clinical Trials
111 clinical trials for Advanced Malignancies across international registries, including 20 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants who were Previously Treated for Advanced Malignancies — RECRUITING · PHASE2
- Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE4
- Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies — RECRUITING · PHASE1
- An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers — RECRUITING · PHASE1
- A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies — RECRUITING · PHASE1
- An Extension Study for Patients Previously Enrolled in Studies With Pelabresib — RECRUITING · PHASE3
- BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) — RECRUITING · PHASE1
- A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies — RECRUITING · PHASE1
- A Study of BR111 in Patients With Advanced Malignancies — RECRUITING · PHASE1
- A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer — RECRUITING · PHASE1
- A PHASE 1/1B FIRST-IN-HUMAN TRIAL OF BMS-986484 AS MONOTHERAPY AND
COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID MALIGNANCIES — RECRUITING · PHASE1
- A Study of IBI363 in Subjects With Advanced Malignancies — RECRUITING · PHASE1
- A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer — RECRUITING · PHASE1
- AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE THE SAFETY OF SGN 35T IN ADULTS WITH ADVANCED MALIGNANCIES — RECRUITING · PHASE1
- AN OPEN-LABEL, PHASE 2 BASKET STUDY OF SEA-CD40 COMBINATION THERAPIES IN ADVANCED MALIGNANCIES — RECRUITING · PHASE2
- PHASE I/II STUDY OF THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY CLINICAL ACTIVITY OF BT8009 IN PATIENTS WITH NECTIN-4 EXPRESSING ADVANCED MALIGNANCIES — RECRUITING · PHASE1
- AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE LB STUDY TO ASSESS THE SAFETY AND PHARMACOKINETICS OF SUBCUTANEOUS DELIVERY OF AMIVANTAMAB, A HUMAN BISPECIFIC EGFR AND CMET ANTIBODY FOR THE TREATMENT OF ADVANCED SOLID MALIGNANCIES — RECRUITING
- CANADIAN ATEZOLIZUMAB PRECISION TARGETING FOR IMMUNOTHERAPY INTERVENTION: CAPTIV-8. — RECRUITING
- A PHASE I/IB, OPEN-LABEL, MULTI-CENTER DOSE ESCALATION STUDY OF NIS793 IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES — RECRUITING · PHASE1
- A PHASE I-IB/II, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF MBG453 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES — RECRUITING · PHASE1
- A Phase 1 clinical trial to test the safety, preliminary effects of increasing doses of AZD7648 alone and in combination with other anti-cancer agents in patients with advanced cancers.. — OTHER · PHASE2
- Vaccination with peptides (molecules) and other ingredients which stimulate the anticancer immune system in patients with advanced cancers — COMPLETED · PHASE1
- An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B) — TERMINATED · PHASE3
- A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors — NOT_YET_RECRUITING · PHASE1
- Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers — ACTIVE_NOT_RECRUITING · PHASE1
- Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing — ACTIVE_NOT_RECRUITING · PHASE3
- Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies — COMPLETED · PHASE1
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies — COMPLETED · PHASE3
- AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE PF-07994525 IN PARTICIPANTS WITH ADVANCED MALIGNANCIES — NOT_YET_RECRUITING · PHASE1
- Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies — NOT_YET_RECRUITING · PHASE1
- Clinical Study of BR105 Injection — TERMINATED · PHASE1
- A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects with Advanced Malignancies — TERMINATED · PHASE1
- Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
- Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies — COMPLETED · PHASE1
- A PHASE 1B / 2, MULTICENTER, MULTI ARM STUDY OF EVORPACEPT IN COMBINATION WITH ANTI-CANCER THERAPIES IN ADVANCED / METASTATIC MALIGNANCIES / A SINGLE-ARM PHASE 2 MULTICENTER STUDY OF EVORPACEPT IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC HER2-POSITIVE BREAST CANCER — NOT_YET_RECRUITING · PHASE2
- Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) — TERMINATED · PHASE1
- AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE PF-08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES — COMPLETED · PHASE1
- A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors — COMPLETED · PHASE1
- Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies — COMPLETED · PHASE1
- Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen — COMPLETED · PHASE1
- Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies — COMPLETED · PHASE1
- A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies — OTHER · PHASE1
- Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels — COMPLETED · PHASE1
- Phase I/II Clinical Study of 1A46 Drug Substance — TERMINATED · PHASE1
- Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies — COMPLETED · PHASE1
- A Clinical Study of MIL95 in Advanced Malignancies. — OTHER · PHASE1
- A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies — TERMINATED · PHASE1
- The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. — TERMINATED · PHASE2
- A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS120, which is an Antibody medication, to be administered alone or with Pembrolizumab in Subjects with Advanced Malignancies — OTHER · PHASE1
- A Clinical Study of MIL93 in Solid Tumors. — OTHER · PHASE1
Refine this search